Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy

Paolo Giorgi-Rossi, Monica Merito and Piero Borgia

Health Policy, 2009, vol. 89, issue 2, 225-238

Abstract: Objective To examine the health outcomes and costs of a hypothetical pneumococcal vaccination campaign among the general infant population in the Lazio region (Italy).Methods We developed a model simulating direct medical costs and health outcomes of vaccinating infants with conjugated pneumococcal vaccine (PCV-7) compared to the costs (in and outpatient) of treating the disease, from a public health service perspective. According to vaccine trials' outcomes, we considered vaccine effectiveness in preventing part of the invasive pneumococcal disease (IPD), pneumonia of any aetiology, and acute otitis moedia. Age-specific incidence, mortality and health care costs came from local surveillance and surveys; the vaccine costs [euro]40/dose. Annual budgetary impact and macro-health benefits were predicted for 2005-2014. Cost-effectiveness was expressed as net healthcare costs per disability-adjusted life-year (DALY) gained.Results After 10 years, five cases of meningitis, 20 IPD, 933 pneumonia, 406 pneumonia-related hospitalisations, and 3160 otitis cases would be averted annually by vaccinating. The annual cost of vaccination would be [euro]4.9Â m, and annual costs averted would be [euro]1.4Â m. Additional healthcare costs of a mass vaccination would decrease over time from [euro]5.1Â m to [euro]3.5Â m per year. At baseline, net cost per averted DALY was [euro]18.0Â k, if health benefits are not discounted, and [euro]51.7Â k adopting a 3.5% discount rate; it was 12% lower with a hypothesis of high IPD incidence and 68% lower if the vaccine cost 50% less.Conclusions The cost of the vaccine makes the campaign more expensive than today's recommended infant vaccinations. Nevertheless, the cost-effectiveness of introducing PCV-7 in Lazio compares favourably with previous estimates in similar countries.

Keywords: Cost-effectiveness; Budget; impact; Vaccination; Economic; Conjugate; pneumococcal; vaccine (search for similar items in EconPapers)
Date: 2009
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168-8510(08)00134-6
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:89:y:2009:i:2:p:225-238

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().